AR053477A1 - Cartamo con acido gamma - linolenico elevado - Google Patents

Cartamo con acido gamma - linolenico elevado

Info

Publication number
AR053477A1
AR053477A1 ARP060102090A ARP060102090A AR053477A1 AR 053477 A1 AR053477 A1 AR 053477A1 AR P060102090 A ARP060102090 A AR P060102090A AR P060102090 A ARP060102090 A AR P060102090A AR 053477 A1 AR053477 A1 AR 053477A1
Authority
AR
Argentina
Prior art keywords
seeds
safflower
gla
sequences
linolenic
Prior art date
Application number
ARP060102090A
Other languages
English (en)
Original Assignee
Arcadia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcadia Biosciences Inc filed Critical Arcadia Biosciences Inc
Publication of AR053477A1 publication Critical patent/AR053477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)

Abstract

La presente se refiere a composiciones y métodos para preparar ácido gamma-linoleico (GLA) en plantas de cártamo, particularmente de semillas de cártamo. Las secuencias de ácidos nucleicos y construcciones que codifican una o más secuencias de desaturasas de ácidos grasos se utilizan para generar plantas de cártamo transgénicas que contienen y expresan una o más de estas secuencias y producen altos niveles de GLA en semillas de cártamo. Se proporcionan plantas de cártamo transgénicas y semillas que producen altos niveles de GLA. Se proporcionan además aceites producidos de semillas de la presente. La presente también se refiere a métodos de tratamiento de una variedad de enfermedades incluyendo trastornos del sistema nervioso, afecciones inflamatorias, cáncer y trastornos cardiovasculares utilizando los aceites de la presente.
ARP060102090A 2005-05-23 2006-05-22 Cartamo con acido gamma - linolenico elevado AR053477A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413405P 2005-05-23 2005-05-23
US73598405P 2005-11-10 2005-11-10

Publications (1)

Publication Number Publication Date
AR053477A1 true AR053477A1 (es) 2007-05-09

Family

ID=37452775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102090A AR053477A1 (es) 2005-05-23 2006-05-22 Cartamo con acido gamma - linolenico elevado

Country Status (13)

Country Link
US (2) US7893321B2 (es)
EP (1) EP1885862B1 (es)
JP (1) JP5033122B2 (es)
CN (1) CN101321872B (es)
AR (1) AR053477A1 (es)
AU (1) AU2006249983B2 (es)
BR (1) BRPI0611480B1 (es)
CA (1) CA2609367C (es)
CL (1) CL2007003413A1 (es)
ES (1) ES2550623T3 (es)
HK (1) HK1120823A1 (es)
NZ (1) NZ563676A (es)
WO (1) WO2006127789A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519724A2 (pt) * 2004-12-20 2009-01-20 Basf Plant Science Gmbh polipeptÍdeo isolado, seqÜÊncia de Ácido nucleico isolada, Ácido nucleico isolado, vetor de expressço, mÉtodos de produzir uma planta transgÊnica e de modular o nÍvel de uma porcentagem em peso de composto de armazenagem de semente em uma planta, planta transgÊncia, e, semente
WO2008006171A1 (en) 2006-07-14 2008-01-17 Commonwealth Scientific And Industrial Research Organisation Altering the fatty acid composition of rice
JP2011519552A (ja) * 2008-04-25 2011-07-14 ビーエーエスエフ プラント サイエンス ゲーエムベーハー 植物種子油
US8148121B2 (en) * 2008-08-01 2012-04-03 E.I. Du Pont De Nemours And Company Δ6 desaturases and their use in making polyunsaturated fatty acids
NZ631696A (en) * 2012-04-25 2017-02-24 Grains Res & Dev Corp High oleic acid oils
NZ631702A (en) 2012-06-15 2017-01-27 Grains Res & Dev Corp Production of long chain polyunsaturated fatty acids in plant cells
WO2015087058A1 (en) * 2013-12-10 2015-06-18 The University Of York Desaturase nucleic acids and polypeptides
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
UA122768C2 (uk) 2013-12-18 2021-01-06 Коммонвелз Сайнтіфік Енд Індастріал Рисерч Организейшн Екстрагований рослинний ліпід, що містить довголанцюгові поліненасичені жирні кислоти
AU2019417798A1 (en) * 2018-12-28 2021-07-22 Nippon Suisan Kaisha, Ltd. Dihomo-γ-linolenic acid-containing microbial oil with reduced arachidonic acid content

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034322A (en) 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US4743548A (en) 1984-09-25 1988-05-10 Calgene, Inc. Plant cell microinjection technique
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4943674A (en) 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
US5068193A (en) 1985-11-06 1991-11-26 Calgene, Inc. Novel method and compositions for introducing alien DNA in vivo
US4795855A (en) 1985-11-14 1989-01-03 Joanne Fillatti Transformation and foreign gene expression with woody species
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
US5565347A (en) 1986-06-10 1996-10-15 Calgene, Inc. Transformation and foreign gene expression with plant species
ATE316144T1 (de) 1987-10-20 2006-02-15 Bayer Bioscience Nv 5'-flankierende region eines genes von arabidopsis, das für einen 2s albumin-prekursor kodiert
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5106739A (en) 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5175095A (en) 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
US6355861B1 (en) 1991-10-10 2002-03-12 Rhone-Poulenc Agrochimie Production of gamma linolenic acid by a Δ6-desaturase
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5792922A (en) 1992-04-02 1998-08-11 Sembiosys Genetics Inc. Oil-body protein cis-elements as regulatory signals
US5539092A (en) 1992-10-02 1996-07-23 Arch Development Corporation Cyanobacterial and plant acetyl-CoA carboxylase
ES2148323T3 (es) 1993-02-26 2000-10-16 Calgene Llc Sistema de expresion de un gen a base de geminivirus.
US6051754A (en) 1997-04-11 2000-04-18 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US5972664A (en) 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US5968809A (en) 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US6432684B1 (en) 1997-04-11 2002-08-13 Abbott Laboratories Human desaturase gene and uses thereof
ATE297994T1 (de) 1997-04-11 2005-07-15 Calgene Llc Verfahren und zusammensetzungen für die synthese von langkettigen, mehrfach ungesättigten fettsäuren in pflanzen.
US6075183A (en) 1997-04-11 2000-06-13 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
CN100482797C (zh) * 1997-04-15 2009-04-29 联邦科学和工业研究组织 植物脂肪酸环氧化酶及其用途
EP1019517B2 (en) 1997-09-30 2014-05-21 The Regents of The University of California Production of proteins in plant seeds
US6653530B1 (en) * 1998-02-13 2003-11-25 Calgene Llc Methods for producing carotenoid compounds, tocopherol compounds, and specialty oils in plant seeds
US6492108B1 (en) 1998-03-26 2002-12-10 Incyte Genomics, Inc. Delta-6 desaturase homologs
DK1086236T3 (da) * 1998-06-12 2007-12-03 Calgene Llc Polyumættede fedtsyrer i planter
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US6403349B1 (en) * 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
US6342657B1 (en) 1999-05-06 2002-01-29 Rhone-Poulenc Agro Seed specific promoters
DE50013231D1 (de) * 1999-06-07 2006-09-07 Basf Plant Science Gmbh Delta6-acetylenase und delta6-desaturase aus ceratodon purpureus
US6815579B1 (en) * 1999-07-22 2004-11-09 The University Of British Columbia Plant long chain fatty acid biosynthetic enzyme
US6777591B1 (en) 1999-08-27 2004-08-17 Sembiosys Genetics Inc. Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter
KR20020073580A (ko) * 2000-02-09 2002-09-27 바스프 악티엔게젤샤프트 신규 연장효소 유전자 및 다가불포화 지방산의 제조 방법
DE10102337A1 (de) * 2001-01-19 2002-07-25 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren, neue Biosynthesegene sowie neue pflanzliche Expressionskonstrukte
MXPA03006663A (es) 2001-01-25 2004-05-31 Abbott Lab Genes de desaturasa y usos de los mismos.
US6635451B2 (en) 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
BR0212339A (pt) * 2001-09-05 2006-05-23 Monsanto Technology Llc promotor 7s alfa especìfico para semente na expressão de genes em plantas
PL1633876T3 (pl) 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
PT2166069T (pt) * 2003-08-01 2016-09-13 Basf Plant Science Gmbh Método de produção de ácidos gordos polinsaturados em organismos transgénicos

Also Published As

Publication number Publication date
US7893321B2 (en) 2011-02-22
EP1885862A4 (en) 2009-02-25
NZ563676A (en) 2011-01-28
WO2006127789A2 (en) 2006-11-30
US20110129428A1 (en) 2011-06-02
US8192964B2 (en) 2012-06-05
CN101321872B (zh) 2012-09-05
AU2006249983B2 (en) 2011-03-17
JP5033122B2 (ja) 2012-09-26
CA2609367A1 (en) 2006-11-30
BRPI0611480B1 (pt) 2016-06-07
JP2008545411A (ja) 2008-12-18
WO2006127789A9 (en) 2012-03-01
CL2007003413A1 (es) 2008-07-25
BRPI0611480A2 (pt) 2010-09-14
CN101321872A (zh) 2008-12-10
CA2609367C (en) 2014-08-19
HK1120823A1 (en) 2009-04-09
US20070067870A1 (en) 2007-03-22
AU2006249983A1 (en) 2006-11-30
WO2006127789A3 (en) 2007-11-29
ES2550623T3 (es) 2015-11-11
EP1885862B1 (en) 2015-07-29
EP1885862A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
AR053477A1 (es) Cartamo con acido gamma - linolenico elevado
AR091482A1 (es) Celulas modificadas geneticamente y metodos par su obtencion
CL2017000465A1 (es) Generación de plantas haploides
AR103446A1 (es) Método para modificar con precisión una planta a través de la expresión transitoria de genes
AR075356A1 (es) Promotores inducibles por patogenos y su uso en el mejoramiento de la resistencia a las enfermedades en plantas
AR101331A1 (es) Composiciones y métodos para incrementar el crecimiento y rendimiento de las plantas
BR112015023378A2 (pt) métodos de modular sementes de plantas e conteúdo nectário
AR059650A1 (es) Plantas que presentan aumento en el rendimiento y metodo para lograrlo
AR076273A1 (es) Genes vegetales de la proteina quinasa relacionados con el gen sfn-1
AR105760A1 (es) Métodos y constructos para la modificación específica de ácidos nucleicos en plantas
CR5812A (es) Induccion de esterilidad masculina en plantas mediante expresion de elevados niveles de adivina
AR053279A1 (es) Regulacion post-transcripcional de la expresion genica
CO2018001264A2 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos
AR104572A1 (es) Gen de resistencia al tizón tardío de solanum americanum y métodos de uso
AR069787A1 (es) Proteinas del metabolismo de los lipidos, combinaciones de proteinas del metabolismo de los lipidos y sus usos
CL2017002320A1 (es) Archaebacteria en alimento para animales bioactivo, método para hacer la composición y métodos que emplean la composición
AR037982A1 (es) Composicion que comprende una secuencia de acido nucleico aislado que codifica una sintetasa de acido graso de ciclopropano; organismo, vegetal, celula vegetal, semilla y bacteria transformados; aceite obtenido de dicho vegetal y dicha bacteria; metodo para expresar la sintetasa y metodo para reduci
EA201991714A1 (ru) Регуляторные элементы растений и их использование
AR052203A1 (es) Nuevos miembros de la familia de desaturasa de acido graso omega - 3 y usos de estos
AR114072A1 (es) Plantas con genes dhs modificados
CL2015000016A1 (es) Plantas brassica con composición de aceite de semilla modificada
AR110616A1 (es) Composiciones y métodos para generar un haploide de una planta objeto
AR075126A1 (es) Metodo para el mejor uso del potencial de produccion de plantas transgenicas
AR096230A1 (es) Composiciones y métodos para implementar una mezcla de semillas transgénicas de refugio
UY37295A (es) Promotor vegetal y 3’ utr para la expresión de transgenes

Legal Events

Date Code Title Description
FG Grant, registration